Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has demonstrated encouraging results in clinical trials; however, it isn't approved just yet.While the optimism surrounding the drug made Viking's stock a hot buy early last year, things have drastically cooled over the past six months during which it has plummeted more than 50%. As a result, the stock is now down 65% from its 52-week high of $89.10. Is this a good time to buy shares of Viking Therapeutics, or could more of a decline be coming this year?Making a bullish case for Viking Therapeutics stock isn't difficult. VK2735 has helped participants in a phase 2 trial lose around 15% of their body weight -- and that's without a plateau observed, meaning that even higher weight loss is possible. That was over the course of just a 13-week study; over a longer time frame, it may perform even better.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool